⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

Published 23/04/2024, 20:00
© Reuters Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
PFE
-
MRNA
-
BNTX
-

Benzinga - by Vandana Singh, Benzinga Editor.

Moderna Inc. (NASDAQ:MRNA) is set to clash with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a pivotal London patent trial concerning the development of COVID-19 vaccines.

The High Court is slated to address a legal complaint brought by Moderna. It alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development, a claim Pfizer and BioNTech have refuted by asserting patent invalidity.

Related: Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge.

This legal showdown is part of a global series of intellectual property disputes revolving around mRNA technology.

This technology has been a revenue generator for the pharmaceutical industry, notably benefiting major players like Moderna, Pfizer, and BioNTech.

If successful, Moderna stands to gain a portion of the profits derived from Pfizer and BioNTech’s joint vaccine, Comirnaty.

This could potentially influence similar litigations worldwide and enhance the reputations of the prevailing parties, the Financial Times notes.

Moderna’s lawsuit in London is not aimed at halting the use of the Pfizer/BioNTech vaccine but seeks acknowledgment of patent infringement and compensation.

With declining sales of its Spikevax product, Moderna eyes royalties from Comirnaty to offset losses.

The outcome of this legal battle extends beyond financial gains, potentially shaping the future landscape of mRNA-based products, particularly in areas like cancer treatment and autoimmune diseases.

While a verdict in the London case is pending, previous decisions have not uniformly favored Moderna, indicating prolonged litigation.

A parallel trial in May will delve into Moderna’s amendment of its intellectual property pledge, a move contested by Pfizer and BioNTech, underscoring the complexity and novelty of the legal dispute.

Read Next: Moderna’s Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial.

Price Action: PFE shares are up 0.13% at $26.30, and MRNA stock is up 3.57% at $ 108.19 at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo via Wikimedia Commons

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.